Novavax, Inc. (NASDAQ:NVAX) was upgraded by investment analysts at BidaskClub from a “sell” rating to a “hold” rating in a report released on Monday.
Several other analysts also recently commented on NVAX. Zacks Investment Research downgraded shares of Novavax from a “buy” rating to a “hold” rating in a research report on Friday, June 9th. Piper Jaffray Companies restated a “hold” rating and set a $1.50 price objective on shares of Novavax in a research report on Wednesday, July 26th. Chardan Capital reiterated a “neutral” rating and issued a $1.50 price target on shares of Novavax in a report on Thursday, July 27th. Ladenburg Thalmann Financial Services upgraded shares of Novavax from a “neutral” rating to a “buy” rating and set a $1.60 price target for the company in a report on Wednesday, August 9th. Finally, ValuEngine downgraded shares of Novavax from a “sell” rating to a “strong sell” rating in a report on Friday, June 2nd. One analyst has rated the stock with a sell rating, seven have given a hold rating, four have given a buy rating and one has assigned a strong buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus price target of $5.24.
Shares of Novavax (NVAX) opened at 1.01 on Monday. The firm has a 50-day moving average of $1.14 and a 200 day moving average of $1.14. The firm’s market capitalization is $292.80 million. Novavax has a 52 week low of $0.73 and a 52 week high of $8.49.
Novavax (NASDAQ:NVAX) last posted its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.16) EPS for the quarter, hitting the consensus estimate of ($0.16). Novavax had a negative net margin of 1,006.00% and a negative return on equity of 787.38%. The company had revenue of $6.70 million during the quarter, compared to analysts’ expectations of $6.15 million. During the same quarter in the previous year, the business posted ($0.29) EPS. The firm’s revenue was up 168.0% on a year-over-year basis. On average, equities research analysts expect that Novavax will post ($0.62) EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This story was originally posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this story on another publication, it was illegally stolen and republished in violation of U.S. and international copyright legislation. The correct version of this story can be read at https://stocknewstimes.com/2017/08/16/novavax-inc-nvax-lifted-to-hold-at-bidaskclub.html.
Several institutional investors have recently made changes to their positions in the stock. Raymond James Financial Services Advisors Inc. increased its position in shares of Novavax by 49.8% in the second quarter. Raymond James Financial Services Advisors Inc. now owns 89,697 shares of the biopharmaceutical company’s stock valued at $103,000 after buying an additional 29,800 shares during the period. Profund Advisors LLC increased its position in shares of Novavax by 0.4% in the second quarter. Profund Advisors LLC now owns 120,775 shares of the biopharmaceutical company’s stock valued at $139,000 after buying an additional 455 shares during the period. Canada Pension Plan Investment Board purchased a new position in shares of Novavax during the first quarter valued at about $157,000. Voya Investment Management LLC increased its position in shares of Novavax by 18.6% in the second quarter. Voya Investment Management LLC now owns 138,270 shares of the biopharmaceutical company’s stock valued at $159,000 after buying an additional 21,639 shares during the period. Finally, HighTower Advisors LLC increased its position in shares of Novavax by 3.8% in the first quarter. HighTower Advisors LLC now owns 142,000 shares of the biopharmaceutical company’s stock valued at $184,000 after buying an additional 5,250 shares during the period. 50.49% of the stock is owned by institutional investors.
Novavax Company Profile
Novavax, Inc is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases.
Receive News & Ratings for Novavax Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
